Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

Item

http://www.wikidata.org/entity/Q30357731

Q30357731

about

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma UK guidelines for the management of bone sarcomas Immunotherapy of Childhood Sarcomas Osteosarcoma: Current Treatment and a Collaborative Pathway to Success Advances in the management of osteosarcoma Review of Osteosarcoma and Current Management Immunotherapy for Bone and Soft Tissue Sarcomas Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases Osteosarcoma Overview.Treatment pathway of bone sarcoma in children, adolescents, and young adults Collaborative Pediatric Bone Tumor Program to Improve Access to Specialized Care: An Initiative by the Lebanese Children's Oncology Group.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study.Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Follow-up practices for high-grade extremity Osteosarcoma.Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.How do you design randomised trials for smaller populations? A framework.Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials Future directions in the treatment of osteosarcoma.Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.Sarcoma immunotherapy: past approaches and future directions.An update on chemotherapy for osteosarcoma.BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Novel insights and therapeutic interventions for pediatric osteosarcoma.Drugs in early clinical development for the treatment of osteosarcoma.A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Osteosarcoma: lessons learned and future avenues.Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment.

P2860

Q26750631-D5260B93-8BE4-4CBE-8FCC-0E1EA05B7086 Q26752425-BD8E9E0B-8EAF-4BC7-ABF8-53946E879B16 Q26795369-275B60C7-7E94-4B06-B1BA-D517DDFB1147 Q26797555-BBEA81F1-178F-4BA4-AA16-84EDFB0633ED Q28067644-9636D2A5-6567-4E9F-87FF-927146F43191 Q28077590-69AA99E6-1714-47D9-A9BF-801F9DC10EE6 Q28088363-0D23A672-F573-4F3C-80F5-A64B2107EB40 Q29027136-38CCA45E-39E7-4C85-B09A-83FA0C84C908 Q30235105-1143B71D-2433-432B-B185-CF73F0D52741 Q33434899-C7CC7B0A-A33C-4CE7-95AA-8754F39F2F32 Q33692066-4EFE3E9A-1218-484C-B35F-3A5C325043F1 Q33715651-A32E3B23-BE3B-4798-A5B1-47F73497F306 Q33725511-08C627C5-FBA9-4A23-92E9-731DBF064354 Q33835657-43099D5C-3D6E-4D53-BA7B-86B45D31ACBC Q33859567-9FE35D8F-5436-4F3B-B140-6F73877D0861 Q35005741-22303191-0A33-4B23-A162-9EF8F7279D65 Q35138344-DE63E8DF-182F-4ECB-A85D-46E5C4192458 Q35506606-C33F8B11-5982-465A-99A6-997877760A05 Q35848126-F2084B44-DC89-4B80-95F1-852AAB077DEA Q35894540-B2223A31-EC70-47E5-95A4-5FF5F1E9A8FB Q36011314-7E1CF44B-66CF-45E5-9FA0-EA4738B929E2 Q36078941-A86C0482-F9FA-411E-A9D4-1D0D94FC36B9 Q36203629-C5C2417F-6B2A-4224-9EB0-30D1A92126C5 Q36316518-3F56F00F-4EE2-453B-B8E6-7ADD02B4F558 Q36327357-B1409A8B-E2B7-4EB1-BF65-6FB7A925A3B3 Q36600800-26949C69-AD1B-4627-8E9C-8299B717DD79 Q37362836-3CD09F54-1C23-4BF8-993F-CC78E82DE1F8 Q37471124-9CD8AEE0-2F02-4B2B-87AE-4AD5C283C6C0 Q37733317-BC2B53B5-84C6-4CD6-8CBF-0BB90C8E428E Q38207986-F0C60725-D149-48CC-A288-7247F0CE853D Q38619114-E558DC58-C65E-408E-9F4B-E577A63D9EAE Q38683340-50C26769-C5F3-44F9-AF8B-60AE637243DA Q38736352-7A7CFEBD-FB1E-4153-B6BB-046CB6E97C84 Q38783252-A6EAB3F0-529B-4886-8611-F8C38A27E0F4 Q38819276-EAC087D0-69A9-4515-A4B2-221B9DC722A6 Q38955517-D9D1C19E-1CF8-4FCD-A2FF-8D2159AA8A67 Q39086751-2BB23D91-000E-4343-A98E-CD271EB7F5E5 Q39229404-850AA691-51D4-4E83-9D9C-23948FF7B611 Q39341518-6FC60E38-8EF5-4B98-AC13-86777E668505 Q40306627-0D38E773-CAEA-4C4B-8675-78461CD42511

P2860

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

Item

http://www.wikidata.org/entity/Q30357731

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu